Science Alert
 
Blue
   
Curve Top
International Journal of Pharmacology
  Year: 2022 | Volume: 18 | Issue: 8 | Page No.: 1537-1549
DOI: 10.3923/ijp.2022.1537.1549
 
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Long Non-Coding RNAs: A Double-Edged Sword in Renal Cell Carcinoma Carcinogenesis

Tian Liu and Hui Zhao

Abstract:
Renal cell carcinoma (RCC) is a malignant tumor that results in high mortality and a huge economic burden worldwide. Owing to the paucity of therapy options, it still has a poor prognosis. Therefore, it is of great importance to find an effective strategy for the treatment of RCC. Long Non-Coding RNAs (lncRNAs) emerge as a pivotal regulator of diverse cancers in many biological processes, including proliferation metastasis, apoptosis and metabolism by tethering with DNA, RNA or protein. Recently, a strong body of investigations revealed that lncRNAs play a critical role in carcinogenesis and cancer progression. Hence, this review provides a synopsis of the molecular mechanisms and clinical implications of lncRNAs in the progression of RCC and found that lncRNAs have the potential to be used clinically in RCC in the future.
PDF Fulltext XML References Citation Report Citation
How to cite this article:

Tian Liu and Hui Zhao, 2022. Long Non-Coding RNAs: A Double-Edged Sword in Renal Cell Carcinoma Carcinogenesis. International Journal of Pharmacology, 18: 1537-1549.

DOI: 10.3923/ijp.2022.1537.1549

URL: https://scialert.net/abstract/?doi=ijp.2022.1537.1549

COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 



Curve Bottom